Blog

Tim Martin, Executive VP of Product & Development at Yseop was recently featured in Forbes discussing AI regulation and the EU AI Act.
See how Yseop Copilot is different from other Generative AI technologies across BioPharma and regulated industries.
Generative AI technologies enable the pharmaceutical industry to provide enhanced and quality content automation.
Explore the remarkable milestones and moments that shaped Yseop’s journey in life sciences in 2023.
Yseop recaps Accenture’s Technology Vision 2023 for Biopharma report.
It’s predicted that generative AI could add as much as $4.4 trillion annually to the global economy. We discuss generative AI and the future of work and why it’s important to embrace its benefits.
The adoption of AI in medical writing has been growing in popularity. In fact, by 2030, the global AI in medical writing market is predicted to reach a value of $1.76 billion.
Tim Martin, Executive VP of Product & Development at Yseop was recently featured in Forbes discussing AI regulation and the EU AI Act.
Without a doubt, advanced AI technologies are reimagining the future of medical writing. Historically, medical writers have been faced with inefficient, monotonous processes and have been seeking a solution to save time and ensure accuracy. Enter generative AI, which uses Large Language Models (LLMs) and advanced machine learning to create human-like text, pulling from existing data and experiences to generate new content.
Scroll to Top